BPC-157 vs TB-500
BPC-157 and TB-500 are two of the most-studied peptides in tissue-repair and angiogenesis research. They are frequently compared, and frequently studied together, because they act through different mechanistic routes. This reference contrasts their origin and research focus.
| Aspect | BPC-157 | TB-500 |
|---|---|---|
| Origin | Pentadecapeptide derived from a gastric protein fragment | Synthetic fragment of thymosin β-4 |
| Mechanism class studied | Cytoprotection & angiogenic signaling | Actin regulation & cell migration |
| Primary research focus | Soft-tissue and gut-lining repair models | Tissue remodeling & wound-healing models |
| Often researched with | TB-500 (combination protocols) | BPC-157 (combination protocols) |
| Format | Lyophilized powder | Lyophilized powder |
Different routes to the same research question
BPC-157 is studied largely for cytoprotective and angiogenic signaling, whereas TB-500 (a thymosin β-4 fragment) is studied for its role in actin regulation and cell migration. Because the routes differ, the literature often pairs them — which is why many labs investigate them as a stack.
The combination option
We also stock a combined BPC-157 + TB-500 preparation for protocols that call for both in one vial. See the recovery category for the blend and the individual compounds. View the BPC-157 + TB-500 blend
Questions
For Research Use Only. Not for human or animal consumption. The above is a neutral summary of compound class and published research context; it is not medical, dosing, or usage guidance, and has not been evaluated by the Food and Drug Administration.